Falsified medicines

  • Email
  • Help

Falsified medicines are fake medicines that pass themselves off as real, authorised medicines. The EU has a strong legal framework for the licensing, manufacturing and distribution of medicines, centred around the Directive on falsified medicines for human use, so that only licensed pharmacies and approved retailers are allowed to offer medicines for sale, including legitimate sale via the internet. The European Medicines Agency is working closely with its partners on the implementation of these laws.

Falsified medicines may:

  • contain ingredients of low quality or in the wrong doses;
  • be deliberately and fraudulently mislabelled with respect to their identity or source;
  • have fake packaging, the wrong ingredients, or low levels of the active ingredients.

Falsified medicines do not pass through the usual evaluation of quality, safety and efficacy, which is required for the European Union (EU) authorisation procedure. Because of this, they can be a health threat.

Increase in falsified medicines

Until recently, the most frequently falsified medicines in wealthy countries were expensive 'lifestyle' medicines, such as hormones, steroids and antihistamines. In developing countries, they have included medicines used to treat life-threatening conditions such as malaria, tuberculosis and HIV/AIDS.

The phenomenon of falsified medicines is on the increase, with more and more medicines now being falsified. These include expensive medicines, such as anti-cancer medicines, and medicines in high demand, such as antivirals.

Falsified vs. counterfeit medicines

Falsified medicines are not the same as counterfeit medicines:

  • Falsified medicines are fake medicines that are designed to mimic real medicines;
  • Counterfeit medicines are medicines that do not comply with intellectual-property rights or that infringe trademark law.

EU laws on falsified medicines

The EU has a strong legal framework for the licensing, manufacturing and distribution of medicines. At the end of the distribution chain, only licensed pharmacies and approved retailers are allowed to offer medicines for sale, including the legitimate sale via the internet.

In July 2011, the EU strengthened the protection of patients and consumers by adopting a new Directive on falsified medicines for human use.

This Directive aims to prevent falsified medicines entering the legal supply chain and reaching patients. It introduces harmonised safety and strengthened control measures across Europe by applying new measures, which can be grouped into four main pillars:

1. Safety features of medicines

Barcodes will be printed on or attached to every single pack of medicines subject to prescription and other medicines at risk of being falsified. The barcodes will be checked into a database by the manufacturer and checked out when dispensed by a pharmacy.

These safety features will also allow users to make sure that that the outer packaging has not been tampered with.

2. Supply chain and good distribution practice

The Directive introduces new responsibilities for wholesalers and a definition of brokering activities as well as new responsibilities for brokers. The Agency's revised good-distribution-practice guideline includes specific provisions for brokering activities.

The EudraGMDP database now also includes information on good distribution practice (GDP).

3. Active substances and excipients

From July 2013, all active substances manufactured outside the EU and imported into the EU must be accompanied by a written confirmation from the regulatory authority of the exporting country. These statements are issued per manufacturing site and per active substance and ensure that standards of good manufacurting practice (GMP) equivalent to those in force in the EU are upheld. A number of countries have already committed to issuing written confirmations.

Exporting countries with an 'equivalent' regulatory framework will not need to issue these written confirmations. The European Commission, together with the Agency and Member States, is assessing the regulatory frameworks of countries applying for 'equivalent' status.

The European Commission maintains a webpage detailing the status of the requests received: Quality of medicines and GMP.

4. Internet sales

The Directive has introduced an obligatory logo that will be placed on the websites of legally operating online pharmacies. This logo will allow patients and consumers to identify authorised online pharmacies providing authentic, authorised medicines. Online pharmacy websites will need to be registered with a Member State. Medicines regulatory authorities in Member States will publish lists of authorised internet pharmacies on their websites.

The Agency, along with the Member States, will play an active role in informing the public of this new logo and the official lists of authorised online pharmacies.

The Directive came into force on 21 July 2011. Member States had to start applying these measures in January 2013.

Role of the Agency

The Agency is working closely with the European Commission and the EU Member States to implement this Directive.

This cooperation also includes the European Directorate for the Quality of Medicines and Healthcare (EDQM) and the World Health Organization's International Medical Products Anti-Counterfeiting Taskforce (IMPACT).

The Heads of Medicines Agencies have identified falsified medicines as being a key issue facing the European regulatory network for the five years to 2015. They have stressed that the enforcement of this legislation is the competency of Member States, but that co-ordination between the national and international bodies involved in fighting falsified and counterfeit medicines is necessary:

The Agency is also cooperating with international anti-counterfeiting trade agreements and other criminal-law instruments, such as the Council of Europe's Medicrime convention and the Organisation for Economic Co-operation and Development (OECD) project on counterfeiting and piracy.

Related information